Search results
Adrian JB Brady
Job title: Consultant Cardiologist and Director of the Hypertension Service
Author
Added:
5 months ago
Source:
Radcliffe CVRM
Late-breaking results from the pivotal Phase III FINE-ONE study show that finerenone significantly reduces the urine albumin-to-creatinine ratio (UACR) in adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D).² The findings, presented at the American Society of Nephrology’s Kidney Week 2025, mark the first positive Phase III results for a new therapy in this high-risk…
View more
Kevin Vernooy
Job title: Head of Cardiology
Author
Dirk L Brutsaert
Job title: Professor-Emeritus in the Department of Pharmacology
Author
Shengxian Tu
Author
Ignacio J Amat-Santos
Job title: Director, Cardiac Catheterization & Interventional Cardiology
Author
Author(s):
Ellen Linnea Freese Ballegaard
Added:
11 months ago
ERA 2025 - Dr Ellen Linnea Freese Ballegaard (Copenhagen University Hospital, Copenhagen, DK) joins us to discuss a study investigating guideline-based management of CKD and evaluate the associated risk of cardio-renal outcomes. 315,636 patients were identified from nationwide Danish health care registers between 2011 and 2022 and enrolled in the study. The primary outcome measure was a composite…
View more
Added:
2 weeks ago
Source:
Radcliffe CKM
Mirjam Boros, Radcliffe CardiologyA post hoc secondary analysis of the SOUL trial has found that once-daily oral semaglutide is associated with early and sustained improvements in multiple cardiovascular (CV) risk factors in high-risk patients with type 2 diabetes (T2D).¹ These findings help to explain the mechanisms behind the primary trial results, which showed a 14% reduction in major adverse…
View more
Alexander van Rosendael
Job title: Post Doctoral Researcher
Author
Jose Luis Navia
Job title: Director of Heart and Vascular Center
Author